Molecular basis of TMED9 oligomerization and entrapment of misfolded protein cargo in the early secretory pathway.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
20 Sep 2024
Historique:
medline: 20 9 2024
pubmed: 20 9 2024
entrez: 20 9 2024
Statut: ppublish

Résumé

Intracellular accumulation of misfolded proteins causes serious human proteinopathies. The transmembrane emp24 domain 9 (TMED9) cargo receptor promotes a general mechanism of cytotoxicity by entrapping misfolded protein cargos in the early secretory pathway. However, the molecular basis for this TMED9-mediated cargo retention remains elusive. Here, we report cryo-electron microscopy structures of TMED9, which reveal its unexpected self-oligomerization into octamers, dodecamers, and, by extension, even higher-order oligomers. The TMED9 oligomerization is driven by an intrinsic symmetry mismatch between the trimeric coiled coil domain and the tetrameric transmembrane domain. Using frameshifted Mucin 1 as an example of aggregated disease-related protein cargo, we implicate a mode of direct interaction with the TMED9 luminal Golgi-dynamics domain. The structures suggest and we confirm that TMED9 oligomerization favors the recruitment of coat protein I (COPI), but not COPII coatomers, facilitating retrograde transport and explaining the observed cargo entrapment. Our work thus reveals a molecular basis for TMED9-mediated misfolded protein retention in the early secretory pathway.

Identifiants

pubmed: 39303030
doi: 10.1126/sciadv.adp2221
doi:

Substances chimiques

Membrane Proteins 0
Coat Protein Complex I 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadp2221

Auteurs

Le Xiao (L)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.

Xiong Pi (X)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.

Alissa C Goss (AC)

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Tarick El-Baba (T)

Physical and Theoretical Chemistry Laboratory, University of Oxford, Oxford OX1 3QZ, UK.
Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.

Julian F Ehrmann (JF)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.

Elizabeth Grinkevich (E)

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Silvana Bazua-Valenti (S)

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Valeria Padovano (V)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Seth L Alper (SL)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Division of Nephrology, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School, Boston, MA 02215, USA.

Dominique Carey (D)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Namrata D Udeshi (ND)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Steven A Carr (SA)

Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Juan Lorenzo Pablo (JL)

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Carol V Robinson (CV)

Physical and Theoretical Chemistry Laboratory, University of Oxford, Oxford OX1 3QZ, UK.
Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3QU, UK.

Anna Greka (A)

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Hao Wu (H)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH